Skip to main content
. 2023 Jan 11;12:1094210. doi: 10.3389/fonc.2022.1094210

Figure 6.

Figure 6

NSC59984 treatment results in activation of the PPP. (A) Incorporation of [13C6] glucose into cellular metabolites of ESO26-R248W cells following treatment with NSC59984 (12 μM) for 72 hr was assessed by 1H-13C HSQC NMR. Spectra were normalized to total cellular protein content. B-D: Fold change in total cellular quantities of metabolite intermediates were assessed by IC-FTMS over carrier control set to 1 in: (B) Glycolysis pathway; (C) Pentose phosphate pathway; (D) Adenylates ATP, AMP, and ADP. (E) Fold change in Hexokinase activity following treatment with NSC59984 (12 μM) for 72 hr over carrier control in ESO26-R248W cells. Fold change in carrier-treated cells was normalized to 1. A-E. Paired t-tests were carried out for statistical analysis for each of these assays. * = 0.05, ** = 0.005, *** = 0.0005, **** = 0.00005.